ATE329588T1 - Verwendung von sibutramin zur behandlung von von organischen störungen verursachten zns- erkrankungen - Google Patents

Verwendung von sibutramin zur behandlung von von organischen störungen verursachten zns- erkrankungen

Info

Publication number: ATE329588T1
Authority: AT; Austria
Prior art keywords: sibutramin; diseases caused; cns diseases; treat cns; organic disorders
Prior art date: 1998-12-02

Application number

AT99960633T

Other languages

English (en)

Inventor

Peter Sterling Mueller

Original Assignee

Peter Sterling Mueller

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1998-12-02

Filing date

1999-12-01

Publication date

2006-07-15

1999-12-01 Application filed by Peter Sterling Mueller filed Critical Peter Sterling Mueller

2006-07-15 Application granted granted Critical

2006-07-15 Publication of ATE329588T1 publication Critical patent/ATE329588T1/de

Links

208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title abstract 3
201000010099 disease Diseases 0.000 title 1
VYFYYTLLBUKUHU-UHFFFAOYSA-N dopamine Chemical compound NCCC1=CC=C(O)C(O)=C1 VYFYYTLLBUKUHU-UHFFFAOYSA-N 0.000 abstract 2
QZAYGJVTTNCVMB-UHFFFAOYSA-N serotonin Chemical compound C1=C(O)C=C2C(CCN)=CNC2=C1 QZAYGJVTTNCVMB-UHFFFAOYSA-N 0.000 abstract 2
229940094659 Dopamine reuptake inhibitor Drugs 0.000 abstract 1
210000004556 brain Anatomy 0.000 abstract 1
230000006735 deficit Effects 0.000 abstract 1
208000035475 disorder Diseases 0.000 abstract 1
239000000221 dopamine uptake inhibitor Substances 0.000 abstract 1
239000003112 inhibitor Substances 0.000 abstract 1
238000000034 method Methods 0.000 abstract 1
239000002767 noradrenalin uptake inhibitor Substances 0.000 abstract 1
229940127221 norepinephrine reuptake inhibitor Drugs 0.000 abstract 1
229940126570 serotonin reuptake inhibitor Drugs 0.000 abstract 1
239000003772 serotonin uptake inhibitor Substances 0.000 abstract 1
UNAANXDKBXWMLN-UHFFFAOYSA-N sibutramine Chemical compound C=1C=C(Cl)C=CC=1C1(C(N(C)C)CC(C)C)CCC1 UNAANXDKBXWMLN-UHFFFAOYSA-N 0.000 abstract 1
229960004425 sibutramine Drugs 0.000 abstract 1
208000024891 symptom Diseases 0.000 abstract 1
230000009885 systemic effect Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/08—Antiepileptics; Anticonvulsants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/20—Hypnotics; Sedatives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
- A61P25/36—Opioid-abuse
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Veterinary Medicine (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Medicinal Chemistry (AREA)
Organic Chemistry (AREA)
General Chemical & Material Sciences (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Engineering & Computer Science (AREA)
Biomedical Technology (AREA)
Neurosurgery (AREA)
Neurology (AREA)
Epidemiology (AREA)
Addiction (AREA)
Psychiatry (AREA)
Endocrinology (AREA)
Diabetes (AREA)
Oncology (AREA)
Psychology (AREA)
Communicable Diseases (AREA)
Pain & Pain Management (AREA)
Ophthalmology & Optometry (AREA)
Anesthesiology (AREA)
Hematology (AREA)
Obesity (AREA)
Virology (AREA)
Reproductive Health (AREA)
Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

AT99960633T 1998-12-02 1999-12-01 Verwendung von sibutramin zur behandlung von von organischen störungen verursachten zns- erkrankungen ATE329588T1 (de)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US09/204,124 US6323242B1 (en)	1998-12-02	1998-12-02	Treatment of disorders secondary to organic impairments

Publications (1)

Publication Number	Publication Date
ATE329588T1 true ATE329588T1 (de)	2006-07-15

Family

ID=22756736

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
AT99960633T ATE329588T1 (de)	1998-12-02	1999-12-01	Verwendung von sibutramin zur behandlung von von organischen störungen verursachten zns- erkrankungen

Country Status (8)

Country	Link
US (2)	US6323242B1 (de)
EP (1)	EP1135115B1 (de)
JP (1)	JP2003504303A (de)
AT (1)	ATE329588T1 (de)
AU (1)	AU764049B2 (de)
CA (1)	CA2353133C (de)
DE (1)	DE69931957T2 (de)
WO (1)	WO2000032178A2 (de)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6339106B1 (en) *	1999-08-11	2002-01-15	Sepracor, Inc.	Methods and compositions for the treatment and prevention of sexual dysfunction
US6696495B2 (en) *	1998-12-02	2004-02-24	Snowden Pharmaceuticals, Llc	Treatment of disorders secondary to organic impairments
US6552087B1 (en) *	1999-03-19	2003-04-22	Abbott Gmbh & Co. Kg	Therapeutic agent comprising (+)-sibutramine
US6803387B1 (en) *	1999-03-19	2004-10-12	Abbott Gmbh & Co. Kg	Treatment of neuropathic pain or fibromyalgia
US6503894B1 (en)	2000-08-30	2003-01-07	Unimed Pharmaceuticals, Inc.	Pharmaceutical composition and method for treating hypogonadism
CA2438816A1 (en)	2001-02-22	2002-09-06	Classen Immunotherapies, Inc.	Improved algorithms and methods for products safety
US7842307B2 (en) *	2001-08-06	2010-11-30	Purdue Pharma L.P.	Pharmaceutical formulation containing opioid agonist, opioid antagonist and gelling agent
US6602911B2 (en) *	2001-11-05	2003-08-05	Cypress Bioscience, Inc.	Methods of treating fibromyalgia
US6635675B2 (en) *	2001-11-05	2003-10-21	Cypress Bioscience, Inc.	Method of treating chronic fatigue syndrome
WO2003047560A1 (en) *	2001-11-30	2003-06-12	Eli Lilly And Company	Use of norepinephrine reuptake inhibitors for the treatment of tic disorders
WO2003086372A2 (en) *	2002-04-10	2003-10-23	University Of Florida	Methods of treating medication-, substance-, disease-, and other medical condition-related sexual dysfunction
WO2003090743A1 (en) *	2002-04-24	2003-11-06	Cypress Bioscience, Inc.	Prevention and treatment of functional somatic disorders, including stress-related disorders
CA2484482C (en)	2002-05-30	2011-07-26	Neurosearch A/S	Triple monoamine reuptake inhibitors for the treatment of chronic pain
US20070032554A1 (en) *	2003-08-27	2007-02-08	Elililly And Company A Corporation	Treatment of stuttering and other communication disorders with norepinephrine reuptake inhibitors
US20080269306A1 (en) *	2004-12-27	2008-10-30	Alpha 2 Pharmaceutica Ab	Antidepressant Medicament Comprising Idazoxan and a Selective Serotonin Reuptake Inhibitor
JPWO2007034910A1 (ja) *	2005-09-22	2009-03-26	エーザイ・アール・アンド・ディー・マネジメント株式会社	過食症及び過食症に伴ううつ病の治療用医薬組成物
DK2450041T3 (en)	2005-10-12	2018-11-19	Unimed Pharmaceuticals Llc	Enhanced testosterone gel for use in the treatment of hypogonadism
WO2008034142A2 (en)	2006-09-15	2008-03-20	Reviva Pharmaceuticals, Inc.	Synthesis, methods of using, and compositions of cycloalkylmethylamines
WO2008042773A2 (en) *	2006-09-29	2008-04-10	Pdxrx, Inc.	Unitary pharmaceutical composition, method, and kit for the treatment or prevention of metabolic or endocrine disorders
US20110046120A1 (en) *	2006-10-26	2011-02-24	Mclean Hospital Corporation	Treatment of impulse control disorders
WO2012003501A2 (en)	2010-07-02	2012-01-05	Reviva Pharmaceuticals, Inc.	Compositions, synthesis, and methods of using cycloalkylmethylamine derivatives
KR20140110014A (ko)	2011-12-30	2014-09-16	레비바 파마슈티칼스, 아이엔씨.	페닐시클로알킬메틸아민 유도체의 조성물, 합성, 및 사용 방법
US11033554B2 (en) *	2015-07-24	2021-06-15	United States Government As Represented By The Department Of Veterans Affairs	Use of dopamine and serotonin receptor antagonists for treatment in a subject with retinal degeneration
WO2017168174A1 (en)	2016-04-02	2017-10-05	N4 Pharma Uk Limited	New pharmaceutical forms of sildenafil
CN111343979A (zh)	2017-09-07	2020-06-26	Nls-1制药公司	用于海洛因依赖和物质使用障碍的马吲哚治疗

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US4443449A (en)	1981-04-06	1984-04-17	The Boots Company Limited	Arylcyclobutylalkylamines and anti-depression composition and methods using same
ZA821577B (en)	1981-04-06	1983-03-30	Boots Co Plc	Therapeutic agents
GB8531071D0 (en)	1985-12-17	1986-01-29	Boots Co Plc	Therapeutic compound
GB8704777D0 (en)	1987-02-28	1987-04-01	Boots Co Plc	Medical treatment
JP2675573B2 (ja)	1988-03-31	1997-11-12	科研製薬株式会社	脳機能改善剤
IE61928B1 (en)	1988-11-29	1994-11-30	Boots Co Plc	Treatment of obesity
US5114976A (en)	1989-01-06	1992-05-19	Norden Michael J	Method for treating certain psychiatric disorders and certain psychiatric symptoms
US5668117A (en)	1991-02-22	1997-09-16	Shapiro; Howard K.	Methods of treating neurological diseases and etiologically related symptomology using carbonyl trapping agents in combination with previously known medicaments
US5780051A (en)	1992-04-02	1998-07-14	Dynagen, Inc.	Methods and articles of manufacture for nicotine cessation and monitoring nicotine use
AU4542993A (en) *	1992-06-23	1994-01-24	Sepracor, Inc.	Methods and compositions for treating depression and other disorders using optically pure (+) sibutramine
AU4542893A (en)	1992-06-23	1994-01-24	Sepracor, Inc.	Methods and compositions for treating depression and other disorders using optically pure (-) sibutramine
US5459164A (en)	1994-02-03	1995-10-17	Boots Pharmaceuticals, Inc.	Medical treatment
GB9402641D0 (en)	1994-02-11	1994-04-06	Boots Co Plc	Therapeutic agents
US5663178A (en)	1995-02-06	1997-09-02	Eli Lilly And Company	Tetrahydro-beta carbolines
GB9406857D0 (en)	1994-04-07	1994-06-01	Sandoz Ltd	Improvements in or relating to organic compounds
GB9619757D0 (en)	1996-09-21	1996-11-06	Knoll Ag	Chemical process
GB9619961D0 (en)	1996-09-25	1996-11-13	Knoll Ag	Medical treatment
US5908830A (en)	1996-10-31	1999-06-01	Merck & Co., Inc.	Combination therapy for the treatment of diabetes and obesity
US5795880A (en)	1996-12-30	1998-08-18	Louisiana State University Medical Center Foundation	Method and composition for treating obesity and related disorders in animals comprising dehydroepiandrosterone (DHEA), or a derivative thereof, and an anorectic agent
US5804596A (en)	1997-02-27	1998-09-08	Sabinsa Corporation	Method of preparing a forskohlin composition from forskohlin extract and use of forskohlin for promoting lean body mass and treating mood disorders
US5922341A (en)	1997-10-28	1999-07-13	Vivus, Incorporated	Local administration of pharmacologically active agents to treat premature ejaculation
US6331571B1 (en) *	1998-08-24	2001-12-18	Sepracor, Inc.	Methods of treating and preventing attention deficit disorders
US6075028A (en)	1999-09-23	2000-06-13	Graham; Richard	Method of treating Tourette's syndrome and related CNS disorders

1998
- 1998-12-02 US US09/204,124 patent/US6323242B1/en not_active Expired - Lifetime
1999
- 1999-12-01 CA CA002353133A patent/CA2353133C/en not_active Expired - Fee Related
- 1999-12-01 AT AT99960633T patent/ATE329588T1/de not_active IP Right Cessation
- 1999-12-01 AU AU17488/00A patent/AU764049B2/en not_active Ceased
- 1999-12-01 WO PCT/US1999/028362 patent/WO2000032178A2/en not_active Ceased
- 1999-12-01 EP EP99960633A patent/EP1135115B1/de not_active Expired - Lifetime
- 1999-12-01 DE DE69931957T patent/DE69931957T2/de not_active Expired - Lifetime
- 1999-12-01 JP JP2000584874A patent/JP2003504303A/ja active Pending
2001
- 2001-04-17 US US09/836,156 patent/US20030207943A1/en not_active Abandoned

Also Published As

Publication number	Publication date
US20030207943A1 (en)	2003-11-06
AU1748800A (en)	2000-06-19
US6323242B1 (en)	2001-11-27
EP1135115B1 (de)	2006-06-14
CA2353133A1 (en)	2000-06-08
DE69931957D1 (de)	2006-07-27
WO2000032178A3 (en)	2000-10-05
AU764049B2 (en)	2003-08-07
EP1135115A2 (de)	2001-09-26
CA2353133C (en)	2009-11-03
WO2000032178A2 (en)	2000-06-08
DE69931957T2 (de)	2007-01-25
JP2003504303A (ja)	2003-02-04

Legal Events

Date	Code	Title	Description
2006-12-15	RER	Ceased as to paragraph 5 lit. 3 law introducing patent treaties

Publication	Publication Date	Title
ATE329588T1 (de)	2006-07-15	Verwendung von sibutramin zur behandlung von von organischen störungen verursachten zns- erkrankungen
ATE324908T1 (de)	2006-06-15	Verwendung von anti-rubeola antkörpern zur behandlung von symptomen von erkrankungen des zentralen nervensystems
ATE492279T1 (de)	2011-01-15	Bupropinmetaboliten zur behandlung von dementia und anderen zerebrovasckulären erkrankungen
DE60044152D1 (de)	2010-05-20	Bupropion Metaboliten zur Behandlung von Angstzuständen
DE60027431D1 (de)	2006-05-24	Verwendung von p38 MAPK Inhibitoren in der Behandlung von Augenkrankheiten
ATE207352T1 (de)	2001-11-15	Nicht-allosterische gaba a agonisten zur behandlung von schlafstörungen
NO20044470L (no)	2004-11-04	Terapeutisk anvendelse av selektive PDE 10 inhibitorer
ATE307592T1 (de)	2005-11-15	Epiallopregnanolon zur behandlung von krankheiten des cns
NO2012015I1 (no)	2012-09-11	Dapoxetine i en hver form beskyttet av basis patent nr 330562
UA70925C2 (uk)	2004-11-15	Спосіб лікування естрогенстимульованого раку
ATE390928T1 (de)	2008-04-15	Zusammensetzungen zur behandlung von hauterkrankungen
DE69929464D1 (de)	2006-04-06	Zyklische polyamine zur behandlung der thrombozytopenie
DE60312736D1 (de)	2007-05-03	1,2,4-triaminobenzolderivate zur behandlung von erkrankungen des zentralnervensystems
ATE554169T1 (de)	2012-05-15	Smad7-inhibitoren zur behandlung von krankheiten des zns
ATE338036T1 (de)	2006-09-15	Zur behandlung hyperproliferativer erkrankungen geeignete benzofuran- und benzothiophenderivate
ATE260653T1 (de)	2004-03-15	Verwendung von naaladase inhibitoren zur behandlung von angstzuständen und gedächtnisstörungen
ATE210984T1 (de)	2002-01-15	Verwendung von serotonin- und dopaminrezeptorblockern zur behandlung von mentalen erkrankungen verursacht durch zerebrovaskuläre erkrankungen
EA200200948A1 (ru)	2003-02-27	Лечение псориаза
DE69736180D1 (de)	2006-08-03	Behandlung von manischen erkrankungen
DE60220825D1 (de)	2007-08-02	Verwendung von norepinephrinwiederaufnahmehemmern zur behandlung von ticks
ATE345135T1 (de)	2006-12-15	Tropan-derivate mit dopamin-wiederaufnahme-hemmer-wirkung für die behandlung von ischämischen erkrankungen
NO20061425L (no)	2006-03-29	Kombinasjonen av en serotonin-reopptaksinbibitor og loxapin
ES2180643T3 (es)	2003-02-16	Procedimiento para tratar la disfuncion cognitiva.
DE60108241D1 (de)	2005-02-10	Felabamat-derivate zur behandlung von neuropathischem schmerz
DE60129846D1 (de)	2007-09-20	Isochinolin-aroylpyrrole für die behandlung von krankheiten des zentralnervensystems